Taiwanese Study Finds That Oseltamivir (Tamiflu) Increases Risk of New Onset of Type 2 Diabetes
Nikhil Prasad Fact checked by:Thailand Medical News Team Jan 18, 2025 9 hours, 39 minutes ago
Medical News: Researchers from Chung Shan Medical University and Kaohsiung Medical University in Taiwan, along with the National Taiwan University, have explored a potential link between the widely used influenza medication oseltamivir and the development of diabetes. This large-scale study, leveraging data from the Taiwan National Health Insurance Research Database (NHIRD), has uncovered significant insights into how oseltamivir might influence the risk of diabetes, particularly Type 2 diabetes.
Taiwanese Study Finds That Oseltamivir (Tamiflu) Increases Risk of New Onset of Type 2 Diabetes
Influenza, a global health burden responsible for up to 650,000 deaths annually, is often managed with neuraminidase inhibitors like oseltamivir. The antiviral drug, known for its efficacy and oral bioavailability, plays a vital role in reducing symptoms and complications when administered early. Despite its benefits, emerging research raises concerns about its broader metabolic impacts, leading to this
Medical News report examining the potential risks associated with its use.
Key Findings of the Study
The study analyzed 1,631,968 patients, including 815,984 oseltamivir users, over a decade-long period from 2009 to 2018. Participants were meticulously matched for age and gender, with adjustments for comorbidities such as dyslipidemia, hypertension, and obesity. Researchers employed Cox proportional hazards regression models to investigate the association between oseltamivir use and diabetes development.
The findings revealed:
-Increased Risk of Type 2 Diabetes: Oseltamivir users demonstrated a statistically significant 2.4% higher risk of developing Type 2 diabetes compared to non-users. The hazard ratio (HR) stood at 1.024, with a p-value of 0.037, indicating a reliable association.
-No Link to Type 1 Diabetes: Unlike Type 2 diabetes, no significant correlation was found between oseltamivir use and Type 1 diabetes (HR = 1.021; p = 0.6795).
-Comorbidities Amplify Risks: Conditions such as dyslipidemia (HR = 1.306), chronic liver disease (HR = 1.463), hypertension (HR = 1.607), and obesity (HR = 2.8) significantly increased the likelihood of developing diabetes in oseltamivir users.
The Mechanisms Behind the Findings
The researchers hypothesize that oseltamivir’s impact on glucose metabolism may stem from its inhibition of neuraminidase-1 (Neu-1), an enzyme critical for insulin receptor activation. Neu-1 facilitates insulin signaling by forming a platform with matrix metalloproteinase-9 (MMP-9). By inhibiting Neu-1, oseltamivir could disrupt insulin signaling, leading to impaired glucose uptake and hyperglycemia. This mechanism aligns with previous animal studies where oseltamivir induced glucose intolerance and elevated blood sugar levels.
Additionally, transient hyperglycemia observed in some clinical cases supports this hypothesis. For instance, pediatric patients on oseltami
vir have shown elevated glucose levels, though the short-term nature of treatment raises questions about its long-term effects.
Influenza, Diabetes, and Oseltamivir’s Role
It’s important to consider that the increased diabetes risk may not solely result from oseltamivir. Influenza itself can exacerbate glycemic variability and inflammation, which are known risk factors for diabetes. Patients with pre-existing conditions like obesity or prediabetes are particularly vulnerable, and the physiological stress from severe influenza might contribute to diabetes onset.
Implications for High-Risk Populations
The study highlights the need for cautious use of oseltamivir, particularly in populations predisposed to diabetes. Individuals with conditions such as obesity or metabolic syndrome, who already have heightened risks for Type 2 diabetes, may require additional monitoring during and after oseltamivir treatment.
The study also underscores the complexity of disentangling the effects of the medication from those of the infection itself. Oseltamivir is commonly prescribed for diabetic patients to reduce the severity of influenza-related complications. However, the researchers recommend further investigations to establish whether the observed risks are directly attributable to the drug or to underlying health conditions exacerbated by influenza.
Limitations and Future Research
While the study provides groundbreaking insights, it also acknowledges several limitations:
-Retrospective Design: The analysis is insufficient to establish causality, as retrospective studies cannot definitively determine whether oseltamivir causes diabetes or merely correlates with its occurrence.
-Missing Data: Key clinical indicators, such as baseline glucose levels or HbA1c, were unavailable, which could have provided a clearer picture of patients' metabolic states before treatment.
-Potential Confounders: Factors like lifestyle, socioeconomic status, and concurrent medications were not accounted for, potentially influencing the results.
The researchers suggest prospective cohort studies and randomized controlled trials to further validate these findings. Additionally, mechanistic studies on oseltamivir’s effects on insulin signaling pathways could help clarify its role in diabetes development.
Conclusion
This study marks a significant step in understanding the potential metabolic implications of oseltamivir, a cornerstone in influenza management. While it confirms an association between oseltamivir use and an increased risk of Type 2 diabetes, it emphasizes that further research is needed to establish causality and elucidate the underlying mechanisms. These findings could inform clinical guidelines and encourage more personalized approaches to managing influenza, especially in high-risk populations.
The study findings were published in the peer-reviewed journal: Pharmaceuticals.
https://www.mdpi.com/1424-8247/18/1/128
For the latest Drug News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/ciprofloxacin-has-detrimental-effects-on--mitochondrial-genome
https://www.thailandmedical.news/news/breaking-news-azithromycin-induces-asthma-remission-in-groundbreaking-australian-clinical-trial
https://www.thailandmedical.news/news/drug-induced-myoclonus-a-comprehensive-review
https://www.thailandmedical.news/news/canadian-study-finds-that-most-present-drugs-used-for-glaucoma-treatments-can-cause-adverse-issues
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
